Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving a person discharging managerial responsibility, specifically regarding changes in beneficial ownership of the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. S M Bicknell. On October 8, 2012, he acquired 11 Ordinary Shares through the re-investment of dividends under Personal Equity Plans at a price of 1451.5 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director and managerial responsibility transactions.
Investor Verification Points
- Verify the share price of 1451.5 pence per share on October 8, 2012, to confirm the transaction value.
- Confirm the total beneficial interest held by Mr. S M Bicknell following this acquisition of 11 shares.
- Note that this filing does not reflect the company's broader financial health or operational results for the period.